Omnicell completed the acquisition of 340B Link from Pharmaceutical Strategies Group for $225m.

Omnicell, a provider of medication management solutions and adherence tools for health systems and pharmacies, completed the acquisition of 340B Link, a provider of software-enabled services and solutions to hospitals, health systems and clinics, from Pharmaceutical Strategies Group, a pharmacy intelligence and technology company, for $225m. "The importance of the 340B program continues to grow as covered entities need solutions to help manage rising healthcare costs and uncompensated care. The addition of these distinct capabilities and software-enabled services to our portfolio positions Omnicell to support our health system partners in managing an increasingly complex medication management supply chain with critical capabilities to support 340B compliance and the associated eligible drug cost savings,” Randall Lipps, Omnicell Chairman, President, CEO, and Founder.